Overall, despite several efforts to producing SIRT3 inhibitors, there is a shortage of small molecular compounds suitable for cancer treatment by targeting the inhibitor, which indicating that there are numerous problems in developing the SIRT3 inhibitor. The gene discussed is SIRT3; the disease is cancer.